|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Allelic variation at the CYP2D6 gene has been reported to be associated with Parkinsons' disease (PD) and Lewy body dementia (LBD), but not with Alzheimer's disease (AD).
|
10071712 |
1999 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The combined alleles frequency of CYP2D6*3 + apoE4 was significantly higher not only in the PD group (33.3%) but also in patients with parkinsonism (22.3%) compared to control subjects (1.6%).
|
10353349 |
1999 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Whilst an elevated frequency of the CYP2D6*4 allele was found in Parkinson's disease, no such elevations were found in DLB or Alzheimer's disease.
|
10208640 |
1999 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Seventeen mutations occurring alone or in various combination on 14 alleles of CYP2D6 have been identified in patients with sporadic PD.
|
10091614 |
1999 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This comprehensive study of CYP2D6 mutations demonstrates that other genes or shared environmental exposures account for the familial risk of PD.
|
10435495 |
1999 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To investigate the relationship between CYP2D6 genotypes (reported to be associated with the susceptibilities to Parkinson's disease and multisystem atrophy) and the possible susceptibility to neuroleptic malignant syndrome (NMS) and subacute myelo-optico-neuropathy (SMON), we analyzed the CYP2D6 gene by polymerase chain reaction and restriction fragment length polymorphism in Japanese schizophrenia patients with a history of NMS.
|
9892857 |
1999 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Using allele-specific multiplex PCR, we genotyped 186 subjects for CYP2D6 *3, *4, *6, *7, and *8 alleles in order to estimate allelic, genotype and predicted phenotype frequencies in the control and patient groups, and to investigate the possible statistical difference between Parkinson's disease patients (n=41) and healthy controls (n=145).
|
11097352 |
2000 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated the association of Parkinson's disease (PD) with two genes encoding liver-detoxifying enzymes, debrisoquine 4-hydroxylase (CYP2D6) and N-acetyltransferase 2 (NAT2), and with one gene related to Alzheimer's disease, apolipoprotein E (APOE).
|
10928584 |
2000 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our result supports the hypothesis that the CYP2D6 gene is not a major gene responsible for PD.
|
11295783 |
2001 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, we suggest that CYP2D6*4 polymorphism does not confer susceptibility to PD in the Korean population.
|
11442888 |
2001 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Polymorphic activities of debrisoquine 4-hydroxylase were suggested to be associated with some complex diseases, such as cancer and Parkinson's disease.
|
11702057 |
2001 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Thus, a meta-analysis was conducted to determine if polymorphism, other than the B-mutation, within the CYP2D6 gene confers a greater susceptibility to PD outcome among Asian populations.
|
14557687 |
2003 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although they are based on a small group of subjects with the joint exposure, our findings are consistent with a gene-environment interaction disease model according to which (1) pesticides have a modest effect in subjects who are not CYP2D6 poor metabolizers, (2) pesticides' effect is increased in poor metabolizers (approximately twofold), and (3) poor metabolizers are not at increased PD risk in the absence of pesticide exposure.
|
14991823 |
2004 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
CTD_human |
Although they are based on a small group of subjects with the joint exposure, our findings are consistent with a gene-environment interaction disease model according to which (1) pesticides have a modest effect in subjects who are not CYP2D6 poor metabolizers, (2) pesticides' effect is increased in poor metabolizers (approximately twofold), and (3) poor metabolizers are not at increased PD risk in the absence of pesticide exposure.
|
14991823 |
2004 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Interaction between GSTM1-null and CYP2D6-deficient alleles in the pathogenesis of Parkinson's disease.
|
15061826 |
2004 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
CTD_human |
Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson's disease.
|
15174030 |
2004 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Meanwhile, epidemiological studies from China have shown that the prevalence of PD is much lower than in the Caucasian population, explained by the low frequency of cytochrome P-450 CYP2D6 debrisoquine hydroxylase gene polymorphism.
|
15829184 |
2005 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Data from our group and others suggest that the CYP2D6 PM genotype interacts with certain environmental factors such as pesticide exposure and cigarette smoking to confer differential risk for PD.
|
17017524 |
2006 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Allelic variation at the CYP2D6 gene has been suggested to be associated with CNS disorders, including Parkinson's disease and Lewy body dementia.
|
16337409 |
2006 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
There was no relationship between CYP2D6 alleles and the age of onset and advancement of dementia in AD and PD.
|
17530572 |
2007 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We also found that the cytochrome P450 2D6 gene could have a modifying effect on the risk of PD among persons exposed to pesticides.
|
17502288 |
2007 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms of catechol-0-methyltransferase (COMT), monoamine oxidase B (MAOB), N-acetyltransferase 2 (NAT2) and cytochrome P450 2D6 (CYP2D6) gene in patients with early onset of Parkinson's disease.
|
17270484 |
2007 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
No significant association was found between CYP2D6 genotype and PD, but subjects with extensive metabolizer (EM) CYP2D6 phenotype, and the variant GSTP1*B genotype were at significantly higher PD risk than the corresponding poor or intermediary metabolizers (CYP2D6 poor metabolizer phenotype+intermediary metabolizers).
|
17250723 |
2007 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study does not support an association between PD and mutations of the CYP2D6 and HFE genes, although a weak association cannot be excluded.
|
18300942 |
2008 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Multivariate logistic regression analysis revealed that heterozygous genotypes of cytochrome P4502D6*4(CYP2D6*4), CYP2E1*5B (RsaI) polymorphism and homozygous mutant genotypes of CYP2E1*6 (Dra1) were found to be overrepresented in PD cases when compared to the controls.
|
18327668 |
2008 |